Table 3.
Data comparison between studies comparing IBD incidence from FIT screening programs.
| n | Rodriguez-Lago et al. | Bedi et al. |
|---|---|---|
| 110 | 191 | |
| Median age | 57 | 58 |
| Smoking history (%) | 10 | 12 |
| Ulcerative Colitis (%) | 71.8 | 30.4 |
| Crohn’s Disease (%) | 21.8 | 57.1 |
| IBDU (%) | 6.4 | 12.5 |
| UC distribution | ||
| Proctitis (%) | 32 | 25.8 |
| Left-sided (%) | 33 | 37.9 |
| Extensive/pancolitis (%) | 35 | 36.2 |
| CD distribution | ||
| Ileal (%) | 42 | 14.7 |
| Colonic (%) | 37 | 45 |
| Ileocolonic (%) | 21 | 40.3 |
| Upper gastrointestinal tract (%) | 0 | 0 |
| Perianal (%) | 0 | 0 |
| TI intubation (%) | 38 | 71.2 |
| Any treatment (%) | 73.6 | 64.9 |
| Oral Mesalamine (%) | 57.2 | 48.7 |
| Rectal Mesalamine (%) | 30.9 | 17.8 |
| Steroids (%) | 14.5 | 18.3 |
| Azathioprine (%) | 5.5 | 6.8 |
| Methotrexate (%) | 0.9 | 2.6 |
| Biologic (%) | 1.8 | 17.8 |
| Surgery (%) | 1.8 | 2.1 |
| Follow-up period, median (months) | 25 | 25 |
Significant values are in bold.
UC ulcerative colitis, CD Crohn’s disease, IBDU Inflammatory Bowel Disease unclassified, TI terminal ileum.